Prostate-specific antigen (PSA) values can act as an early surrogate for prostate cancer-specific mortality, and allow for early identification of those who would benefit from long-term androgen suppression therapy, researchers say.
Experts have previously viewed long-term therapy, which is associated with more toxic effects than short-term (six months) therapy, as producing only a small survival benefit.
Therefore, the authors of a new study, which included authors from Australia and New Zealand, say it is vital to identify as soon as possible those who would be candidates for long-term androgen suppression.
Their assessment of a cohort of 734 men with localised or locally advanced prostate cancer, found those treated with radiotherapy and six months of androgen suppression were significantly less likely to have PSA...
This site is intended for Registered Medical Practitioners.
To make the most of Oncology Update, you need to be logged in.